Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma × Potassium Iodide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 2 Pheochromocytoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1

Interventions

Cyclophosphamide 296 Rituximab 271 Etoposide 149 Filgrastim 142 fludarabine phosphate 119 Cytarabine 109 Vincristine 107 Melphalan 102 Radiotherapy 101 Doxorubicin 97 Peripheral Blood Stem Cell Transplantation 93 Methotrexate 91 Prednisone 86 fludarabine 85 Busulfan 85 Tacrolimus 65 Mycophenolic Acid 61 Granulocyte Colony-Stimulating Factor 60 Antilymphocyte Serum 58 Dexamethasone 57 Whole-Body Irradiation 54 Carmustine 54 Bortezomib 45 Cyclosporine 43 Lenalidomide 41 Methylprednisolone 40 sargramostim 39 Bendamustine Hydrochloride 37 ibritumomab tiuxetan 34 Ifosfamide 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00490009 2017-03-30

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Stanford University

Phase 2 Completed

9 enrolled 10 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡